loading
전일 마감가:
$117.18
열려 있는:
$118.82
하루 거래량:
1.20M
Relative Volume:
1.07
시가총액:
$6.83B
수익:
$3.99B
순이익/손실:
$463.16M
주가수익비율:
16.91
EPS:
7.1
순현금흐름:
$1.10B
1주 성능:
+8.35%
1개월 성능:
-5.05%
6개월 성능:
+8.69%
1년 성능:
+9.85%
1일 변동 폭
Value
$118.75
$120.67
1주일 범위
Value
$111.20
$120.67
52주 변동 폭
Value
$95.49
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
명칭
Jazz Pharmaceuticals Plc
Name
전화
353-1-634-7800
Name
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
직원
2,800
Name
트위터
@jazzpharma
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
JAZZ's Discussions on Twitter

JAZZ을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
120.05 6.83B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-07 업그레이드 UBS Neutral → Buy
2025-02-26 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2025-02-13 업그레이드 Wells Fargo Equal Weight → Overweight
2024-12-12 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-06-05 개시 Goldman Buy
2024-01-03 개시 Robert W. Baird Outperform
2023-11-27 다운그레이드 UBS Buy → Neutral
2023-09-29 개시 Raymond James Mkt Perform
2023-06-12 재개 Wells Fargo Equal Weight
2022-12-09 업그레이드 Goldman Neutral → Buy
2022-06-14 개시 UBS Buy
2022-04-06 다운그레이드 Goldman Buy → Neutral
2021-11-19 재개 Goldman Buy
2021-10-07 재개 Jefferies Buy
2021-10-05 개시 Citigroup Buy
2021-09-23 개시 Needham Buy
2021-05-19 재개 JP Morgan Overweight
2021-04-07 재개 RBC Capital Mkts Outperform
2021-02-05 재확인 H.C. Wainwright Buy
2021-02-03 업그레이드 Piper Sandler Neutral → Overweight
2021-01-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-12-16 개시 UBS Buy
2020-11-03 재확인 H.C. Wainwright Buy
2020-10-09 재확인 H.C. Wainwright Buy
2020-09-14 다운그레이드 Goldman Neutral → Sell
2020-09-14 재개 JP Morgan Overweight
2020-08-06 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-07-28 업그레이드 Wolfe Research Peer Perform → Outperform
2020-07-23 업그레이드 H.C. Wainwright Neutral → Buy
2020-04-06 개시 Jefferies Buy
2020-03-12 업그레이드 Bernstein Mkt Perform → Outperform
2020-01-08 개시 Goldman Neutral
2019-08-21 다운그레이드 Piper Jaffray Overweight → Neutral
2019-06-11 개시 Barclays Overweight
2019-03-20 개시 SunTrust Buy
2018-12-14 개시 Wolfe Research Peer Perform
2018-11-08 재확인 B. Riley FBR Buy
2018-08-08 재확인 Stifel Buy
2018-07-11 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2018-03-23 재확인 H.C. Wainwright Neutral
2018-03-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
모두보기

Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스

pulisher
May 01, 2025

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - Eagle-Tribune

May 01, 2025
pulisher
Apr 30, 2025

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference | JAZZ Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Jazz Pharmaceuticals Brings Sleep Disorder and Cancer Treatment Updates to BofA Healthcare Conference - Stock Titan

Apr 30, 2025
pulisher
Apr 30, 2025

Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings - The Globe and Mail

Apr 30, 2025
pulisher
Apr 29, 2025

PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy - insights.citeline.com

Apr 29, 2025
pulisher
Apr 29, 2025

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

3 Unconventional Cannabis Stocks to Watch in 2025 - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

With A 14% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock? - Yahoo Finance

Apr 29, 2025
pulisher
Apr 28, 2025

Antisense Oligonucleotides Market Trends, Growth - openPR.com

Apr 28, 2025
pulisher
Apr 28, 2025

3 Reasons to Sell JAZZ and 1 Stock to Buy Instead - Yahoo Finance

Apr 28, 2025
pulisher
Apr 28, 2025

3 Reasons To Sell JAZZ And 1 Stock To Buy Instead - Barchart.com

Apr 28, 2025
pulisher
Apr 27, 2025

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist? - simplywall.st

Apr 27, 2025
pulisher
Apr 25, 2025

Jazz Pharmaceuticals (JAZZ) Gains European Advisory Support for Zanidatamab | JAZZ Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs - Seeking Alpha

Apr 25, 2025
pulisher
Apr 25, 2025

Jazz Pharmaceuticals Receives Positive EMA Panel Opinion for Zanidatamab to Treat Biliary Tract Cancer - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - PR Newswire

Apr 25, 2025
pulisher
Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025
pulisher
Apr 23, 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma - Placera.se

Apr 23, 2025
pulisher
Apr 23, 2025

Major Cancer Breakthrough: New Phase 3 Data Reveals Significant Survival Benefits in Lung Cancer Treatment - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 | JAZZ Stock News - GuruFocus

Apr 22, 2025
pulisher
Apr 22, 2025

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 - PR Newswire UK

Apr 22, 2025
pulisher
Apr 22, 2025

TD Cowen maintains Jazz stock Buy rating, $100 target By Investing.com - Investing.com UK

Apr 22, 2025
pulisher
Apr 22, 2025

Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma

Apr 22, 2025
pulisher
Apr 22, 2025

Canada Pension Plan Investment Board Purchases 8,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat

Apr 22, 2025
pulisher
Apr 21, 2025

Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 21, 2025

Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider

Apr 21, 2025
pulisher
Apr 21, 2025

Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com

Apr 21, 2025
pulisher
Apr 21, 2025

Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan

Apr 21, 2025
pulisher
Apr 21, 2025

JAZZ Vs. HRMY: Which Neuroscience Drugmaker Is The Stronger Play? - Barchart.com

Apr 21, 2025
pulisher
Apr 21, 2025

JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Yahoo Finance

Apr 21, 2025
pulisher
Apr 17, 2025

Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug - Bloomberg Law News

Apr 17, 2025
pulisher
Apr 17, 2025

JAZZ vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance

Apr 17, 2025
pulisher
Apr 17, 2025

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Yahoo Finance

Apr 17, 2025
pulisher
Apr 17, 2025

Is Jazz Pharmaceuticals A Top Cannabis Investment For 2025? - Barchart.com

Apr 17, 2025
pulisher
Apr 17, 2025

Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? - Zacks Investment Research

Apr 17, 2025
pulisher
Apr 17, 2025

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.

Apr 17, 2025
pulisher
Apr 17, 2025

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance

Apr 17, 2025
pulisher
Apr 15, 2025

Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com

Apr 15, 2025
pulisher
Apr 11, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Apr 11, 2025
pulisher
Apr 11, 2025

Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com

Apr 11, 2025
pulisher
Apr 11, 2025

Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com

Apr 11, 2025
pulisher
Apr 11, 2025

BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK

Apr 11, 2025
pulisher
Apr 10, 2025

Where Jazz Pharmaceuticals Stands With Analysts - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Nasdaq

Apr 10, 2025
pulisher
Apr 09, 2025

Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN

Apr 09, 2025
pulisher
Apr 09, 2025

Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Jazz Pharmaceuticals (JAZZ) Settles Antitrust Claims for $145M - GuruFocus

Apr 09, 2025

Jazz Pharmaceuticals Plc (JAZZ) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Jazz Pharmaceuticals Plc 주식 (JAZZ) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
COZADD BRUCE C
Chairman & CEO
Apr 01 '25
Sale
123.75
1,500
185,625
440,307
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
자본화:     |  볼륨(24시간):